Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04883177Completed

Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

Role: collaborator

NCT05204602Unknown

Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases

Role: collaborator

NCT03406832Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Role: collaborator

NCT03406819Not ApplicableUnknown

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Role: collaborator

All 4 trials loaded